COMPANY

TuHURA Biosciences

Keywords: antibody Merkel cell carcinoma Cutaneous Squamous Cell Carcinoma Advanced Or Metastatic Merkel Cell Carcinoma Stage III Cutaneous Melanoma Stage IV Cutaneous Melanoma Non-Melanoma Skin Cancers Basal Cell Carcinoma IFx-Hu2.0

Location: Tampa, FL · source · Oct 14, 2026

Profile checked Oct 10, 2026

6Trials (company is sponsor)

Funding and NIH signals

SEC Form D raise Raised $1.5M (Form D filed Nov 10, 2025). SEC Form D 0001498382-25-000004 (Nov 10, 2025)
Evidence (1 event)
- Nov 10, 2025 · SEC Form D 0001498382-25-000004
  Name of Issuer: TuHURA Biosciences, Inc./NV; CIK: 1498382; Address: Tampa, FL; Submission type: D; Filing date: 2025-11-10; Industry Group: Biotechnology; Date of First Sale: 2025-10-27; Types of Securities Offered: Equity, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 3000000; Total Amount Sold: 1500000; Federal exemptions: 06b

Job counts as of Oct 18, 2026. All funding and NIH signals

Timeline

Dec 11, 2025 Trial start Phase 2/Phase 3: Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma source ↗
2025-10 Trial start Phase 1: IFx-Hu2.0 As An Adjunctive Therapy To Pembrolizumab In Advanced Or Metastatic Merkel Cell Carcinoma (MCC) source ↗
Jun 10, 2021 Trial start Phase 1: IFx-Hu2.0 for the Treatment of Patients With Skin Cancer source ↗
Mar 3, 2020 Trial start Phase 1: Immunotherapy With IFx-Hu2.0 Vaccine for Advanced Non-melanoma Skin Cancers source ↗
Nov 5, 2018 Trial start Early phase 1: pDNA Intralesional Cancer Vaccine for Cutaneous Melanoma source ↗

Upcoming milestones

Mar 31, 2027 (ESTIMATED) · Phase 2/Phase 3 · Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma · NCT06947928

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 6

Record	Title	Phase	Status	Start	Primary completion
NCT06947928	Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma	Phase 2/Phase 3	Recruiting	Dec 11, 2025	Mar 31, 2027 (estimated)
NCT06940440	IFx-Hu2.0 As An Adjunctive Therapy To Pembrolizumab In Advanced Or Metastatic Merkel Cell Carcinoma (MCC)	Phase 1	Recruiting	2025-10	May 31, 2026 (estimated)
NCT04160065	Immunotherapy With IFx-Hu2.0 Vaccine for Advanced Non-melanoma Skin Cancers	Phase 1	Completed	Mar 3, 2020	Oct 19, 2023 (actual)
NCT04853602	IFx-Hu2.0 Expanded Access Program	Not listed	Available	Not listed	Not listed
NCT04925713	IFx-Hu2.0 for the Treatment of Patients With Skin Cancer	Phase 1	Completed	Jun 10, 2021	Oct 7, 2021 (actual)
NCT03655756	pDNA Intralesional Cancer Vaccine for Cutaneous Melanoma	Early phase 1	Completed	Nov 5, 2018	Jul 10, 2020 (actual)